A new pharmaceutical plant is planned to be built in Almaty with investments of more than ₸39 billion. The project aims to expand drug production and deepen the localization of international developments within the country. The first production launches are scheduled for 2029.
The investment agreement provides for the localization of 40 international non-proprietary drug names, covering 68 production positions across 12 therapeutic areas. In the first stage, spanning 2030 to 2033, the plant will focus on the production of finished dosage forms, technology transfer, and the development of full-cycle production. Between 2029 and 2032, the production of 23 out of the 40 names is planned to be mastered. New production directions including rheumatology, immunology, and the treatment of pulmonary arterial hypertension are planned to open in 2030. The next stage, calculated for 2034 to 2036, involves organizing the production of active pharmaceutical ingredients. In 2032, the launch of six positions for biological drugs is expected, comprising five for oncology and one for hematology.
Project: Localization of pharmaceutical production in Kazakhstan · Kazakhstan · Planned · $370 m
Key facts
- Investment volume exceeds ₸39 billion.
- Location is Almaty, Kazakhstan.
- First launches are scheduled for 2029.
- Project covers 40 international non-proprietary drug names.
- Active pharmaceutical ingredient production is planned for 2034-2036.